RenovoRx quadruples quarterly sales to $1.07m as pancreatic cancer trial finishes enrolling

RenovoRx booked $1.07m in revenue for the third quarter of 2026, roughly four times the $266,000 it recorded a year earlier. The company, which reported on 5 November, credited the rise to commercial uptake of RenovoCath, its FDA-cleared device for delivering drugs directly to a tumour site.

The customer base behind that growth now stands at 26 active cancer centres. RenovoRx left its full-year 2026 revenue guidance unchanged at $3.75m to $4.25m. The third-quarter figure alone is a little over a quarter of the guidance midpoint of $4.0m, though the material available does not break down the earlier quarters.

On the development side, the company said enrolment is complete in TIGeR-PaC, its Phase III trial in locally advanced pancreatic cancer. Top-line results are expected in the second half of 2027, so the study now moves from recruitment into follow-up and analysis.

RenovoRx also reported that the first patient has been treated in an investigator-initiated neoadjuvant study at the University of Vermont. The material available gives no further detail on the design, size or timelines of that study.